- مبلغ: ۸۶,۰۰۰ تومان
- مبلغ: ۹۱,۰۰۰ تومان
Antibiotic-based triple therapy is reasonably eVective in treating patients with symptomatic Helicobacter pylori infection, but this approach is untenable for global control of the infection. In practice, however, anti-H pylori therapy is prescribed to an increasing number of patients, in the absence of proven benefit.1 2 Firstly, anti-H pylori treatment is increasingly oVered to infected patients with non-ulcer dyspepsia and to asymptomatic carriers. This “test-andtreat” attitude is aimed at controlling the dyspeptic symptoms and at reducing long term risk of gastric malignancies in infected individuals. Secondly, anti-H pylori treatment is also advocated as a first approach in H pylori positive dyspeptic patients, in an attempt to reduce the overall management costs of these patients, without prior endoscopic documentation of the presence of an ulcer or of other complications of the infection. Even though some decision analysis and clinical studies suggest that these different approaches may be beneficial, other studies have failed to show potential benefit.